tiakis biotech AG, formerly Proteo Biotech AG, located in the north of Germany, is the next generation preventive therapeutic technology company based on its clinical stage pioneering tissue protective drug 'Tiprelestat', which is identical to a human recombinant anti-inflammatory protein. The company is fully dedicated to its novel therapy approach to treat life-threatening unmet medical need diseases. Our approach represents a paradigm shift towards a preventive approach by e.g. protecting against inflammatory organ damage and failure following invasive major surgery, by offering the potential for reversing the vascular pathology of pulmonary arterial hypertension or by prevention of serious disease progression of COVID-19.